European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research

Vaccine

Volumn 23, Issue 48-49, 2005, Pages 5551-5556

  Lehner, Thomas ^a   Hoelscher, Michael ^b   Clerici, Mario ^c   Gotch, Frances ^d   Pedneault, Louise ^e   Tartaglia, Jim ^f   Gray, Clive ^g   Mestecky, Jiri ^h   Sattentau, Quentin ⁱ   Wijgert, Janneke Van De ^j   Toure, Coumba ^k   Osmanov, Saladin ^k   Schmidt, Reinold E ^l   Debre, Patrice ^m   Romaris, Manuel ⁿ   Hoeveler, Arnd ⁿ   Di Fabio, Simonetta ⁿ  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e GSK   (Belgium)

^f DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^g NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^h Vaccine Centre   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j International Antiviral Therapy Evaluation Center   (Netherlands)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m CNRS   (France)

ⁿ EUROPEAN COMMISSION   (Belgium)

more..

Author keywords

European Commission Strategy; HIV AIDS; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; ENZYME LINKED IMMUNOSPOT ASSAY; FINANCIAL MANAGEMENT; GOOD LABORATORY PRACTICE; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS; DEVELOPING COUNTRIES; EUROPEAN UNION; HEALTH PLANNING GUIDELINES; HIV; HUMANS; SAFETY;

EID: 27744590448     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.009     Document Type: Article

References (12)

1. UNAIDS/WHO. Annual AIDS Epidemic Update December 2004. UNAIDS/WHO, Geneva, Switzerland. http://www.unaids.org/wad2004/report_pdf.html.
2. H.J. Tanne AIDS vaccine is a long way off BMJ 330 2005 1170
3. D.R. Burton, R.C. Desrosiers, P.R. Johnson, and W.C. Koff An AIDS vaccine: no time to give up Lancet 364 2004 1938
4. A.S. Fauci HIV and AIDS: 20 years of science Nat Med 9 2003 839 843
5. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract J Exp Med 200 2004 749 759
6. + T lymphocyte from effector sites in the gastrointestinal tract J Exp Med 200 2004 761 770
7. + T cells Nature 434 2005 1148 1151
8. + T cells in multiple tissues during acute SIV infection Nature 434 2005 1093 1097
9. I.V. Belyakov, and J.A. Berzofsky Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines Immunity 20 2004 247 253
10. P.A. Kozlowski, and M.R. Neutra The role of mucosal immunity in prevention of HIV transmission Curr Mol Med 3 2003 217 228
11. T. Lehner Innate and adaptive mucosal immunity in protection against HIV infection Vaccine 21 2003 68 76
12. R. Veazey, and A. Lackner The mucosal immune system and HIV-1 infection AIDS Rev 5 2003 245 252